NasdaqGM:LNTH

Stock Analysis Report

Executive Summary

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide.


Snowflake Analysis

Good value with reasonable growth potential.


Similar Companies

Share Price & News

How has Lantheus Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LNTH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

15.9%

LNTH

3.7%

US Medical Equipment

2.4%

US Market


1 Year Return

-49.3%

LNTH

-1.6%

US Medical Equipment

-10.0%

US Market

Return vs Industry: LNTH underperformed the US Medical Equipment industry which returned -5.2% over the past year.

Return vs Market: LNTH underperformed the US Market which returned -13.3% over the past year.


Shareholder returns

LNTHIndustryMarket
7 Day15.9%3.7%2.4%
30 Day-6.8%-5.6%-11.0%
90 Day-32.6%-14.5%-19.4%
1 Year-49.3%-49.3%-0.8%-1.6%-8.1%-10.0%
3 Year19.2%19.2%50.7%46.6%17.3%9.6%
5 Yearn/a81.9%63.2%36.1%21.1%

Price Volatility Vs. Market

How volatile is Lantheus Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Lantheus Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: LNTH ($11.09) is trading below our estimate of fair value ($244.36)

Significantly Below Fair Value: LNTH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: LNTH is good value based on its PE Ratio (13.7x) compared to the Medical Equipment industry average (37.5x).

PE vs Market: LNTH is poor value based on its PE Ratio (13.7x) compared to the US market (12.5x).


Price to Earnings Growth Ratio

PEG Ratio: LNTH is good value based on its PEG Ratio (0.4x)


Price to Book Ratio

PB vs Industry: LNTH is overvalued based on its PB Ratio (3.8x) compared to the US Medical Equipment industry average (2.9x).


Next Steps

Future Growth

How is Lantheus Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

33.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LNTH's forecast earnings growth (33.2% per year) is above the savings rate (1.7%).

Earnings vs Market: LNTH's earnings (33.2% per year) are forecast to grow faster than the US market (13.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: LNTH's revenue (12.1% per year) is forecast to grow faster than the US market (7% per year).

High Growth Revenue: LNTH's revenue (12.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LNTH's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Lantheus Holdings performed over the past 5 years?

41.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LNTH has high quality earnings.

Growing Profit Margin: LNTH's current net profit margins (9.1%) are lower than last year (11.8%).


Past Earnings Growth Analysis

Earnings Trend: LNTH has become profitable over the past 5 years, growing earnings by 41.7% per year.

Accelerating Growth: LNTH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: LNTH had negative earnings growth (-21.8%) over the past year, making it difficult to compare to the Medical Equipment industry average (1%).


Return on Equity

High ROE: Whilst LNTH's Return on Equity (27.63%) is high, this metric is skewed due to their high level of debt.


Next Steps

Financial Health

How is Lantheus Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: LNTH's short term assets ($172.9M) exceed its short term liabilities ($66.1M).

Long Term Liabilities: LNTH's short term assets ($172.9M) do not cover its long term liabilities ($225.2M).


Debt to Equity History and Analysis

Debt Level: LNTH's debt to equity ratio (169.1%) is considered high.

Reducing Debt: LNTH had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: LNTH's debt is well covered by operating cash flow (41.5%).

Interest Coverage: LNTH's interest payments on its debt are well covered by EBIT (4x coverage).


Balance Sheet


Next Steps

Dividend

What is Lantheus Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LNTH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LNTH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LNTH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LNTH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LNTH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Mary Heino (59yo)

4.67s

Tenure

US$4,320,908

Compensation

Ms. Mary Anne Heino has been the Chief Executive Officer and President of Lantheus Holdings, Inc. since August 2015. Ms. Heino served as Chief Operating Officer at Lantheus Medical Imaging, Inc. since Marc ...


CEO Compensation Analysis

Compensation vs Market: Mary's total compensation ($USD4.32M) is above average for companies of similar size in the US market ($USD2.21M).

Compensation vs Earnings: Mary's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Mary Heino
CEO, President & Director4.67yrsUS$4.32m1.67% $8.6m
Robert Marshall
CFO & Treasurer1.58yrsUS$1.44m0.22% $1.1m
John Bolla
Chief Operating Officer1.08yrsUS$1.04m0.16% $812.5k
Michael Duffy
Senior VP of Law & Public Policy and General Counsel12.25yrsUS$1.30m0.35% $1.8m
Simon Robinson
Senior Vice President of Research & Pharmaceutical Development2yrsUS$1.01mno data
Mark Kinarney
Director of Investor Relationsno datano datano data
Meara Murphy
Director of Corporate Communicationsno datano datano data
Etienne Montagut
Senior Vice President of Corporate Development1.58yrsno datano data
Carol Walker
Senior Vice President of Quality2yrsno datano data
Istvan Molnar
Chief Medical Officer0.25yrno data0.073% $375.0k

1.8yrs

Average Tenure

54yo

Average Age

Experienced Management: LNTH's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Mary Heino
CEO, President & Director4.67yrsUS$4.32m1.67% $8.6m
Samuel Leno
Independent Director7.92yrsUS$199.99k0.11% $562.0k
Derace Schaffer
Independent Director4.08yrsUS$187.49k0.063% $324.4k
Frederick Robertson
Independent Director4.08yrsUS$194.99k0.12% $627.1k
Brian Markison
Non-Executive Independent Chairman7.25yrsUS$244.99k0.090% $460.9k
Kenneth Pucel
Independent Director2.17yrsUS$182.49k0.054% $276.2k
James Thrall
Independent Director2.17yrsUS$179.99k0.045% $230.9k
James Clemmer
Independent Director4.75yrsUS$192.49k0.16% $802.7k
Julie McHugh
Independent Director3.25yrsUS$189.99k0.060% $308.4k
Gary Pruden
Independent Director2.17yrsUS$189.99k0.046% $234.9k

4.1yrs

Average Tenure

59.5yo

Average Age

Experienced Board: LNTH's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Lantheus Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lantheus Holdings, Inc.
  • Ticker: LNTH
  • Exchange: NasdaqGM
  • Founded: 1956
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$513.535m
  • Shares outstanding: 39.72m
  • Website: https://www.lantheus.com

Number of Employees


Location

  • Lantheus Holdings, Inc.
  • 331 Treble Cove Road
  • North Billerica
  • Massachusetts
  • 1862
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LNTHNasdaqGM (Nasdaq Global Market)YesNew Common StockUSUSDJun 2015
0L8DB (Deutsche Boerse AG)YesNew Common StockDEUSDJun 2015

Biography

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment follow-up of neuroendocrine tumors. It sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. The company has a strategic collaboration and license agreement with NanoMab Technology Limited to provide an imaging biomarker research tool to pharmaceutical companies and academic centers conducting research and development on PD-L1 immuno-oncology treatments. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/09 00:42
End of Day Share Price2020/04/08 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.